Replies to post #6754 on Biotech Values

[DewDiligence]

>>Thanks for the update dew. I would still choose squalamine.<<

If the choice were simply Squalamine vs Macugen, I too would probably choose Squalamine based on the limited data we have so far. (As I’ve previously posted, if I had AMD right now, were in good overall health, and couldn’t get into a clinical trial, I would try to find a doctor who would give me off-label Avastin.)

>>Any idea of the number of responders in the macugen trial that improved > 4,5 etc lines?<<

I don’t recall seeing those figures published, so I would have to check. It’s reasonable to infer that about half of the 6% of Macugen patients who gained 3+ lines gained exactly 3 lines; hence the percent who gained more than 3 lines is presumably in the neighborhood of 3%.